 | • レポートコード：B-MOR-040407 • 出版社/出版日：Mordor Intelligence / 2018年3月 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、骨がん治療の世界市場について調べ、骨がん治療の世界規模、市場動向、市場環境、治療別（化学療法、標的療法、放射線治療、手術）分析、エンドユーザー別（病院、専門クリニック、がん放射線治療センター）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・骨がん治療の世界市場インサイト ・骨がん治療の世界市場環境 ・骨がん治療の世界市場動向 ・骨がん治療の世界市場規模 ・骨がん治療の世界市場規模：治療別（化学療法、標的療法、放射線治療、手術） ・骨がん治療の世界市場規模：エンドユーザー別（病院、専門クリニック、がん放射線治療センター） ・骨がん治療の世界市場：地域別市場規模・分析 ・骨がん治療の北米市場規模・予測 ・骨がん治療のアメリカ市場規模・予測 ・骨がん治療のヨーロッパ市場規模・予測 ・骨がん治療のアジア市場規模・予測 ・骨がん治療の日本市場規模・予測 ・骨がん治療の中国市場規模・予測 ・骨がん治療のインド市場規模・予測 ・骨がん治療の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global bone cancer therapy market is expected to register a CAGR of 6.0% during the forecast period 2018 to 2023. North America dominates the market due to growing prevalence of bone cancer diseases in the region.
Increasing Incidence of Bone Cancer
According to American Cancer Society (ACS), in 2017, an estimated 3,260 people of all ages (1,820 men and boys and 1,440 women and girls) in the United States were diagnosed with primary bone cancer. Around 400 to 1,000 new cases of osteosarcoma are diagnosed annually in the United States and a similar incidence of osteosarcoma has been reported in Europe. Osteosarcoma accounts for about 3-5% of juvenile cancers. Thus growing incidence of bone cancer couple with growing government initiatives for bone cancer awareness, and aging population globally are anticipated to drive the market of global bone cancer.
Unavailability of Effective Treatment Coupled with Side Effects
Osteosarcoma is a relatively rare cancer, however, about 800 to 900 new cases of osteosarcoma are diagnosed in the United States, annually. About 50% are reported in children and teens. The treatment options for these patients are restricted to few options. In addition, the side effects of available treatment options often are significant and may lead to damage of other organs of body or may lead to other health related severe issues. Additionally, cancer cost is expected to grow in the range of 6% to 9%, annually, during forecast period. Thus, unavailability of effective treatment and side effects of cancers drugs along with rising cost of bone cancer is likely to impede the growth of global bone cancer market.
North America to Dominate the Market
North America dominates the global bone cancer therapy market owing to high prevalence of bone cancer in the region and aging population, coupled with high favorable reimbursement policies in the region. Developing countries are expected to account minimum share owing to less awareness regarding bone cancer among the populations and less availability of effective treatment option for bone cancer in the region. However, penetration of key players in the region coupled with aging populations are anticipated to drive the market growth of bone cancer in the emerging countries of Asia Pacific.
Key Developments in the Market
• September 2016: Dr Reddy’s Laboratories (DRL) expanded strategic collaboration with Amgen to market and distribute Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India.
Major Players: AMGEN. ASTRAZENECA, BRISTOL-MEYRS SQUIBB COMPANY, BAYER AG, F. HOFFMANN-LA ROCHE LTD., GLAXOSMITHKLINE PLC, JOHNSON & JOHNSON, MERCK & CO., INC., NOVARTIS AG, PFIZER INC., amongst others.
Reasons to Purchase this Report
• Current and future global bone cancer therapy market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players
• 3 months analyst support along with the Market Estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidence of Bone Cancer
6.1.2 Growing Government Initiatives for Bone Cancer Awareness
6.1.3 Aging Population
6.2 Market Restraints
6.2.1 Unavailability of Effective Treatment Coupled with Side Effects
6.2.2 High Cost of Cancer Therapies
6.3 Market Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Treatment Type
7.1.1 Chemotherapy
7.1.1.1 Doxorubicin
7.1.1.2 Cisplatin
7.1.1.3 Carboplatin
7.1.1.4 Etoposide
7.1.1.5 Ifosfamide
7.1.1.6 Cyclophosphamide
7.1.1.7 Methotrexate
7.1.1.8 Vincristine
7.1.2 Targeted Therapy
7.1.2.1 Denosumab
7.1.2.2 Imatinib
7.1.3 Radiation Therapy
7.1.4 Surgery
7.2 By End User
7.2.1 Hospitals
7.2.2 Specialty Clinics
7.2.3 Cancer and Radiation Therapy Centers
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Actavis plc
9.2 Amgen
9.3 Bayer AG
9.4 F. Hoffmann-La Roche Ltd
9.5 IDM Pharma, SA
9.6 Merck & Co., Inc.
9.7 Novartis AG
9.8 Pfizer Inc.
9.9 Others
10. Future of the Market